医学
多发性骨髓瘤
耐火材料(行星科学)
嵌合抗原受体
抗体
CD38
疾病
癌症研究
肿瘤科
内科学
免疫学
免疫疗法
癌症
干细胞
生物
天体生物学
遗传学
川地34
作者
Pedro Asensi Cantó,Mario Arnao Herraiz,Javier de la Rubia
标识
DOI:10.1016/j.medcli.2023.11.019
摘要
Patients with multiple myeloma who present with refractory disease or relapse after receiving the main classes of available drugs -immunomodulators, proteasome inhibitors and antibodies against CD38- do not have satisfactory therapeutic alternatives. New treatments based on the redirection of T lymphocytes to act directly against tumor cells, such as bispecific antibodies and T cells with chimeric antigen receptors, are changing this scenario. The published information confirms unprecedented antitumor activity of these agents in patients with refractory myeloma and they will certainly represent the backbone of the treatment of these patients in the immediate future. However, these therapies also present specific characteristics and medium or long-term toxicities that pose new healthcare challenges. In this review, we address the current results and future challenges of the administration of these treatments in patients with relapsed or refractory multiple myeloma.
科研通智能强力驱动
Strongly Powered by AbleSci AI